Immunomodulating antibodies and drugs for the treatment of hematological malignancies. - Wikidata - wikimedia - TriplyDB

Immunomodulating antibodies and drugs for the treatment of hematological malignancies.

Immunomodulating antibodies and drugs for the treatment of hematological malignancies.

http://www.wikidata.org/entity/Q37832694

about

Immunomodulation of Selective Naive T Cell Functions by p110δ Inactivation Improves the Outcome of Mismatched Cell Transplantation.CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications.Cancer cell-binding peptide fused Fc domain activates immune effector cells and blocks tumor growth.Combination strategies to enhance antitumor ADCC.Development of anticancer drugs based on the hallmarks of tumor cells.Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody.On the representation of cells in bone marrow pathology by a scalar field: propagation through serial sections, co-localization and spatial interaction analysis.

P2860

Q35973413-88AC6857-6996-4F5E-859D-BDD93F31BC47 Q36204132-0DCD9BCC-3A4F-4D33-982C-7E61E41C70C1 Q37689046-9BA36201-7A2D-42B7-9AD9-6192A56A0A76 Q38014085-1B564AEA-AEDB-4E20-9D76-AAC910F840E2 Q38182491-9E2C8FE4-FBB1-41EE-9038-5582C958D456 Q41474839-515253DB-D22D-432C-8AEB-B8A71F5CC93F Q43045608-2ABAC92B-7EC5-416E-AEDD-FE96E46E40A2

P2860

Immunomodulating antibodies and drugs for the treatment of hematological malignancies.

http://www.wikidata.org/entity/Q37832694

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Immunomodulating antibodies and drugs for the treatment of hematological malignancies.

@en

Immunomodulating antibodies and drugs for the treatment of hematological malignancies.

@nl

type

label

Immunomodulating antibodies and drugs for the treatment of hematological malignancies.

@en

Immunomodulating antibodies and drugs for the treatment of hematological malignancies.

@nl

prefLabel

Immunomodulating antibodies and drugs for the treatment of hematological malignancies.

@en

Immunomodulating antibodies and drugs for the treatment of hematological malignancies.

@nl

P1433

Q37832694-8C30194F-09C7-4B9C-9EFC-293A598F2146

P1476

Q37832694-F21742A8-44BB-4AF9-980D-D5433819F480

P2093

Q37832694-2617A250-9359-40C3-A099-0B6778941F19

Q37832694-34DADDB8-3912-40D4-83EF-A433DB88C8B7

Q37832694-38AD7786-B421-4843-85E5-2143BAFFF6B8

Q37832694-3DCAE248-C52C-4044-988A-9C54D802C60F

P2860

Q37832694-0A2CF2A4-18AD-4F70-A61B-458E327E1095

Q37832694-15849A35-67FB-4254-8C3F-9885FD0FBD8C

Q37832694-1A2200E9-44BB-4A51-A9AE-407FDC2303D7

Q37832694-1A4E24C8-A455-46E4-8FD0-D4B346B80A73

Q37832694-234316DB-34B1-4D62-9CB1-8F9FC11CD287

Q37832694-2551671B-39CD-4DD1-8A39-0DD96CFDDD91

Q37832694-2DA02D4F-DF78-4626-A7B0-FD87D0F50901

Q37832694-2DC30242-AC96-41DC-AEED-918634A85974

Q37832694-31780AC4-40DC-4366-AE77-C5F4CE24BFB5

Q37832694-3221FA57-C708-452A-B8B3-98AC0DB352F9

P2888

Q37832694-8216ED69-7632-49AD-B210-F654CEB3896C

P304

Q37832694-9C75149D-887D-43A1-8CA7-2FAAB8962A87

P31

Q37832694-6D1CE523-523E-4851-9C15-450F8BD05C30

P356

Q37832694-0555195A-8EAF-4D78-B495-90EDB7FDF17E

P433

Q37832694-E3923E91-974D-4040-B5C1-F01330182B48

P478

Q37832694-DB3E6BDC-AA80-4280-A8C6-C0857B985BEF

P577

Q37832694-4A5599AD-BBCC-44F7-A8D2-986CC6C60754

P698

Q37832694-E7BDEDDF-769E-4960-ADA2-A50F52699B00

P921

Q37832694-71AB7655-0BB6-40A1-B52E-FAA5DF1F7753

P356

S10555-011-9274-3

P1433

Cancer and Metastasis Reviews

P1476

Immunomodulating antibodies and drugs for the treatment of hematological malignancies.

@en

P2093

Holbrook Kohrt

http://www.w3.org/2001/XMLSchema#string

Matthew J Goldstein

http://www.w3.org/2001/XMLSchema#string

Roch Houot

http://www.w3.org/2001/XMLSchema#string

Ronald Levy

http://www.w3.org/2001/XMLSchema#string

P2860

Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Cutting edge: Expression of functional CD137 receptor by dendritic cells

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma

Enhancement of antitumor immunity by CTLA-4 blockade

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

Thalidomide and rituximab in Waldenstrom macroglobulinemia

P2888

s10555-011-9274-3

P304

97-109

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10555-011-9274-3

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21271352

http://www.w3.org/2001/XMLSchema#string

P921